Bio-Rad Laboratories has announced the launch of the Bio-Plex Pro Human IgG SARS-CoV-2 N/RBD/S1/S2 4-Plex Panel.
The qualitative multiplex immunoassay kit quickly and efficiently detects IgG antibodies against four SARS-CoV-2 antigens, enabling vaccine developers to determine therapeutic efficacy from development through all clinical phases. In addition, the kit enables public health researchers to perform seroprevalence studies. This could help to identify the number of persons in a population who have been exposed to SARS-CoV-2 based on serology specimens, capturing individuals who have not received a COVID-19 diagnosis due to experiencing only mild symptoms or being asymptomatic.
“Detecting levels of antibodies against SARS-CoV-2 provides useful information about natural exposure rates in a population or about vaccine immunogenicity,” said Candice Cox (Bio-Rad Immunoassays Marketing Manager, Life Science Group). “We are pleased to be able to offer this new immunoassay kit to researchers working in vaccine development and related fields.”